Literature DB >> 27501129

Monoclonal gammopathy of cutaneous significance: review of a relevant concept.

D Lipsker1.   

Abstract

Some dermatologic entities are strongly associated with the presence of a monoclonal gammopathy. They should be referred to as monoclonal gammopathy of cutaneous significance (MGCS). A short review of the main entities that fit into the spectrum of MGCS is provided. Amyloidosis, macroglobulinoderma and follicular hyperkeratotic spicules result from extravascular immunoglobulin or immunoglobulin-related protein deposition. Skin findings include papules and plaques, follicular spicules, purpura, haemorrhagic bullae, macroglossia and nail changes. The skin findings in cryoglobulinemia (CG) result from vascular immunoglobulin deposition, either as immune complexes within the vessel walls in mixed CG or within the lumina of small vessels in monoclonal CG. Mixed CG manifests as palpable purpura of leukocytoclastic vasculitis, and monoclonal CG as stellar and/or retiform purpura that can evolve into extensive skin necrosis. In some rare instances, immunoglobulins have a specific biological activity. This is, for example, the case when they bind lipoproteins that precipitate and induce hypocomplementemic xanthomas. Xanthoderma related to antiflavin activity of the monoclonal component or acquired angioedema related to anti-C1INH activity is other example. Abnormal cytokine secretion is the hallmark of some entities. High vascular endothelial growth factor levels correlate with some of the skin manifestations of the Polyneuropathy organomegaly endocrinopathy monoclonal component skin changes syndrome, such as hypertrichosis or the adenopathy and extensive skin patch overlying plasmacytoma syndrome. All the clinical manifestations of the Schnitzler syndrome are IL-1 mediated. In other MGCS, such as scleromyxedema, Clarkson syndrome, TEMPI syndrome, cutis laxa and the neutrophilic dermatoses, the link between the monoclocal component and the entity is clearly established, but not understood so far.
© 2016 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27501129     DOI: 10.1111/jdv.13847

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  7 in total

Review 1.  Schnitzler Syndrome: a Review.

Authors:  L Gusdorf; D Lipsker
Journal:  Curr Rheumatol Rep       Date:  2017-08       Impact factor: 4.592

2.  A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria.

Authors:  Caroline A Nelson; Connie S Zhong; David A Hashemi; Hovik J Ashchyan; Zoe Brown-Joel; Megan H Noe; Sotonye Imadojemu; Robert G Micheletti; Ruth Ann Vleugels; Karolyn A Wanat; Misha Rosenbach; Arash Mostaghimi
Journal:  JAMA Dermatol       Date:  2020-03-01       Impact factor: 10.282

3.  A case of relapsed systemic multiple myeloma mimicking adenopathy and extensive skin patch overlying a plasmacytoma.

Authors:  Valérie Tremblay-Abel; Janie Bujold; Bernard Delisle
Journal:  JAAD Case Rep       Date:  2022-06-03

Review 4.  Immunoglobulin M Monoclonal Gammopathies of Clinical Significance.

Authors:  Louis-Pierre Girard; Cinnie Yentia Soekojo; Melissa Ooi; Wee Joo Chng; Sanjay de Mel
Journal:  Front Oncol       Date:  2022-06-09       Impact factor: 5.738

5.  Evidence of B Cell Clonality and Investigation Into Properties of the IgM in Patients With Schnitzler Syndrome.

Authors:  Shelly Pathak; Dorota Rowczenio; Samuel Lara-Reyna; Mark Kacar; Roger Owen; Gina Doody; Karoline Krause; Helen Lachmann; Rainer Doffinger; Darren Newton; Sinisa Savic
Journal:  Front Immunol       Date:  2020-12-03       Impact factor: 7.561

6.  Case report: One case of primary AL amyloidosis repeatedly misdiagnosed as scleroderma.

Authors:  Linge Sun; Lei Zhang; Wenlu Hu; Tian-Fang Li; Shengyun Liu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

Review 7.  Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All.

Authors:  Oliver C Lomas; Tarek H Mouhieddine; Sabrin Tahri; Irene M Ghobrial
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.